Does Pretreatment Insomnia or Anxiety Predict Acute Response to Bupropion SR?

References

• Coleman C, Cunningham L, Foster V, Batey SR, Donahue RMJ, Houser T, Ascher J: Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained release and sertraline treatment. Ann Clin Psychiatry 1999; 11:205–215.
   PubMedGoogle Scholar
• Croft H, Settle E, Houser T, Batey SR, Donahue RMJ, Ascher JA: A placebo-controlled comparison of the antidepressant and sexual functioning effects of bupropion sustained release and sertraline. Clin Ther 1999; 21:643–658.
   PubMed Web of Science ®Google Scholar
• Kavoussi RJ, Segraves RT, Hughes AR, Ascher JA, Johnston JA: Double-blind comparison of bupropion SR sustained release and sertraline in depressed outpatients. J Clin Psychiatry 1997; 58: 532–537.
   PubMed Web of Science ®Google Scholar
• Coleman CC, King BR, Bolden-Watson C, Book MJ, Seagraves RT, Richard N, Ascher J, Batey S, Jamerson B, Metz A: A placebo-controlled comparison of the effects on sexual function of bupropion sustained release and fluoxetine. Clin Ther 2001; 23:1040–1058.
   PubMed Web of Science ®Google Scholar
• Feighner JP, Gardner EA, Johnston JA, Batey SR, Khayrallah MA, Ascher JA, Lineberry CG: Double-blind comparison of bupropion and fluoxetine in depressed outpatients. J Clin Psychi-atry 1991; 52:329–335.
   PubMed Web of Science ®Google Scholar
• Weihs KL, Settle EC, Batey SR, Houser TH, Donahue RMJ, Ascher JA: Bupropion SR versus paroxetine for the treatment of depression in the elderly. J Clin Psychiatry 2000; 61:196–202.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association: Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 2000; 157\(suppl 4):1–45.
   Google Scholar
• Depression Guideline Panel: Clinical Practice Guideline, Number 5. Depression in Primary Care: Volume 2. Treatment of Major Depression. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research. AHCPR Publication No. 93–0551; 1993.
   Google Scholar
• Blackwell B: Side effects of antidepressant drugs. In: Hales RE, Frances AJ, eds. Psychiatry update: The American Psychiatric Association Annual review (Vol. 6). Washington, DC: American Psychiatric Press: 1987:724–745.
   Google Scholar
• Zimmerman M, Posternak M, Friedman M, Attiullah N, Baymiller S, Boland R, Berlowitz S, Rahman S, Uy K, Singer S: Which factors influence psychiatrists' selection of antidepres-sants? Am J Psychiatry 2004; 161(7):1285–1289.
   PubMed Web of Science ®Google Scholar
• Rush AT, Batey SR, Donahue RMJ, Ascher JA, Carmody T, Metz A: Does pretreatment anxiety predict response to either bupropion SR or sertraline? J Affect Disord 2001a; 64:81–87.
   Google Scholar
• Rush AJ, Trivedi MH, Carmody TJ, Donahue RMJ, Houser TL, Bolden-Watson C, Batey SR, Ascher JA, Metz A: Response in relation to baseline anxiety levels in major depressive disorder treated with bupropion sustained release or sertraline. Neuropsy-chopharmacology 2001b; 25:131–138.
   PubMed Web of Science ®Google Scholar
• Simon GE, Heiligenstein JH, Grothaus L, Katon W, Revicki D: Should anxiety and insomnia influence antidepressant selection: a randomized comparison of fluoxetine and imipramine. J Clin Psy-chiatry 1998; 59:49–55.
   Google Scholar
• Stokes P, Holtz A: Fluoxetine tenth anniversary update: the progress continues. Clin Ther 1997; 19:1135–1250.
   PubMed Web of Science ®Google Scholar
• Tollefson GD, Greist JH, Jefferson JW, Heiligenstein JH, Sayler ME, Tollefson SL, Koback K: Is baseline agitation a relative contraindication for a selective serotonin reuptake inhibitor: a comparative trial of fluoxetine versus imipramine. J Clin Psych-opharmacol 1994; 14:385–391.
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Rush AJ, Carmody TJ, Donahue RMJ, Bolden-Wat-son C, Houser TL, Metz A: Do bupropion SR and sertraline differ in their effects on anxiety in depressed patients? J Clin Psychiatry 2001; 62:776–781.
   PubMedGoogle Scholar
• Tyrer PJ, Lee I, Edwards JG, Steinberg B, Elliott EJ, Nightingale JH: Prognostic factors determining response to antidepressant drugs in psychiatric outpatients and general practice. J Affect Disord 1980; 2:149–156.
   Google Scholar
• American Psychiatric Association: Practice guidelines for major depressive disorder in adults. Am J Psychiatry 1993; 150\(suppl 4): 1–51.
   Google Scholar
• Koran LM, Gelenberg AJ, Kornstein SG, Howland RH, Friedman RA, DeBattista C, Klein D, Kocsis JH, Schatzberg AF, Thase ME, Rush AJ, Hirschfeld RMA, LaVange LM, Keller MB: Sertraline versus imipramine to prevent relapse in chronic depression. J Affect Disord 2001; 65:27–36.
   PubMed Web of Science ®Google Scholar
• Quitkin FM, Petkova E, McGrath PJ, Taylor B, Beasley C, Stewart J, Amsterdam J, Fava M, Rosenbaum J, Reimherr F, Fawcett J, Chen Y, Klein D: When should a trial of fluoxetine for major depression be declared failed? Am J Psychiatry 2003; 160(4): 734–740.
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Rush AJ, Pan J-Y, Carmody TJ: Which depressed patients respond to nefazodone and when? J Clin Psychiatry 2001; 62:158–163.
   PubMed Web of Science ®Google Scholar
• Weihs KL, Houser TL, Batey SR, Ascher JA, Bolden-Watson C, Donahue RMJ, Metz A: Continuation phase treatment with bupropion SR effectively decreases the risk for relapse of depres-sion. Biol Psychiatry 2002; 51:753–761.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders (4th ed). Washington, DC: American Psychiatric Association; 1994.
   Google Scholar
• Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56–62.
   PubMed Web of Science ®Google Scholar
• Hamilton M: Development of a rating scale for primary depres-sive illness. Br J Soc Clin Psychol 1967; 6:278–296.
   PubMed Web of Science ®Google Scholar
• Hamilton M: The assessment of anxiety states by rating. Br J Med Psychol 1959; 32:50–55.
   PubMed Web of Science ®Google Scholar
• Guy W: ECDEU Assessment Manual for Psychopharmacology. Washington, DC: Superintendent of Documents, U.S. Government Printing Office, U.S. Department of Health, Education and Welfare Publication No. 76–338; 1976.
   Google Scholar
• Kraemer HC: Evaluating medical tests:Objectives and qualitative guidelines. Newbury Park, CA: Sage Publications; 1992.
   Google Scholar
• Dinan TG: Efficacy and safety of weekly treatment with enteric-coated fluoxetine in patients with major depressive disorder. J Clin Psychiatry 2001; 62\(suppl 22):48–52.
   Google Scholar
• Fava M, Rosenbaum JF, Hoog SL, Tepner RG, Kopp JB, Nilsson ME: Fluoxetine versus sertraline and paroxetine in major depres-sion: Tolerability and efficacy in anxious depression. J Affect Disord 2001; 59:119–126.
   Google Scholar
• Filteau MJ, Baruch P. Lapierre YD, Bakish D, Blanchard A: SSRIs in anxious-agitated depression: a post-hoc analysis of 279 patients. Int Clin Psychopharmacol 1995; 10:51–54.
   PubMed Web of Science ®Google Scholar
• Thase ME, Haight BR, Richard N, Modell JG, Mitton M, VanMeter S, Rockett C, Harriet AE, Wang Y: Remission rates following antide-pressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from seven randomized controlled trials. J Clin Psych in press.
   Google Scholar